Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Atrial Appendage Occlusion and Arrhythmia Treatment

a technology of arrhythmia and appendage occlusion, which is applied in the field of atrial appendage occlusion and arrhythmia treatment, can solve the problems of irregular and turbulent blood flow in the vascular system, unable to contract with any vigor, and a rapid and chaotic heartbeat, so as to prevent blood clots

Inactive Publication Date: 2012-11-08
VENTRIMEND INC
View PDF5 Cites 88 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0007]One aspect of the disclosure is an implantable cardiac orifice occlusion and arrhythmia treatment device, comprising: an anchoring portion adapted to anchor the device in place adjacent a cardiac orifice; a barrier element secured to the anchoring portion and adapted to cover the orifice when implanted, and adapted to prevent blood clots from passing through the barrier element; and an arrhythmia treatment element secured to at least one of the anchoring portion and the barrier element, the treatment element adapted to treat a detected cardiac arrhythmia.
[0016]In some embodiments the anchoring step comprises allowing the anchoring portion to deform from a delivery configuration towards a deployed configuration in which it anchors against cardiac tissue.

Problems solved by technology

Atrial fibrillation (“AF”) is an arrhythmia of the heart that results in a rapid and chaotic heartbeat, producing lower cardiac output and irregular and turbulent blood flow in the vascular system.
The LAA normally contracts with the rest of the left atrium during a normal heart cycle, keeping blood from becoming stagnant therein, but often fails to contract with any vigor in patients experiencing AF due to the discoordinate electrical signals associated with AF.
The result is that blood tends to pool in the LAA, which can lead to the formation of blood clots therein.
Since blood from the left atrium and ventricle supply the heart and brain, blood clots from the LAA can obstruct blood flow thereto, causing heart attacks, strokes, or other organ ischemia.
The effectiveness of warfarin, however, is challenged due to serious side effects, lack of patient compliance in taking the medication, a narrow therapeutic window, and an increased risk of bleeding.
Studies, however, have shown these techniques produce inconsistent results.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Atrial Appendage Occlusion and Arrhythmia Treatment
  • Atrial Appendage Occlusion and Arrhythmia Treatment
  • Atrial Appendage Occlusion and Arrhythmia Treatment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0068]The disclosure herein relates to isolating clots to prevent them from entering into an atrium of the heart. While the disclosure focuses on the left atrial appendage (“LAA”) and the left atrium, the systems can be used in the right atrial appendage and the right atrium. The devices may also be used to close other undesirable orifices in the heart, such as Atrial Septal Defects (“ASD”) or Patent Foramen Ovales (“PFO”). They may also be used in other portions of a body unrelated to the heart. The disclosure herein also relates to providing therapy for a detected cardiac arrhythmia to attempt to prevent the formation of clots within the appendage.

[0069]One aspect of the disclosure herein relates to LAA occlusion devices and methods of use. A second aspect of the disclosure herein provides for intra-atrial or intra-LAA cardiac monitoring and therapy for a detected arrhythmia.

[0070]The first aspect can be a stand-alone procedure to occlude the LAA from the left atrium. The second a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Atrial appendage occlusion devices and arrhythmia treatment.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority to U.S. Provisional Patent Application No. 61 / 441,627, filed Feb. 10, 2011, the entire disclosure of which is incorporated by reference herein.INCORPORATION BY REFERENCE[0002]All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.BACKGROUND OF THE DISCLOSURE[0003]Atrial fibrillation (“AF”) is an arrhythmia of the heart that results in a rapid and chaotic heartbeat, producing lower cardiac output and irregular and turbulent blood flow in the vascular system. The left atrial appendage (“LAA”) is a cavity extending from the lateral wall of the left atrium between the mitral valve and the root of the left pulmonary veins. The LAA normally contracts with the rest of the left atrium during a normal heart cycle...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61B5/02A61F2/01
CPCA61B17/0057A61B2017/00243A61B2017/00592A61N1/3756A61B2017/00601A61B2017/00615A61B2017/00597A61P9/06
Inventor WERNETH, RANDELL L.ZARBATANY, DAVID
Owner VENTRIMEND INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products